BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ueno T, Osawa M, Imai Y, Ishikawa H, Garimella T. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection. J Clin Pharmacol 2018;58:1479-88. [PMID: 30063245 DOI: 10.1002/jcph.1262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Ueno T, Osawa M, Shiozaki T, Green M, Garimella T. Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients. Clin Pharmacol Drug Dev 2019;8:903-13. [PMID: 30667592 DOI: 10.1002/cpdd.646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc 2020;119:1593-600. [PMID: 32839045 DOI: 10.1016/j.jfma.2020.08.010] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]